Cassava sciences announces closing of $50 million registered direct offering

Austin, texas, nov. 22, 2022 (globe newswire) -- cassava sciences, inc. (nasdaq: sava) (the “company” or “cassava sciences”), a clinical-stage biotechnology company focused on alzheimer's disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of its common stock, at a purchase price per share of $30, for gross proceeds of approximately $50 million.
SAVA Ratings Summary
SAVA Quant Ranking